SH2D2A encodes T-cell-specific adapter protein (TSAd), a T-cell-specific adapter protein involved in controlling T-cell activation 1. The gene spans 11 kilobases on chromosome 1-1q22 with nine exons and produces four alternative transcript variants in activated T cells 2. TSAd functions as a protein-macromolecule adaptor that facilitates signal transduction downstream of T-cell receptor stimulation, with transcriptional activation critically dependent on a cAMP response element in the proximal promoter 3. Functionally, SH2D2A modulates T-cell activation by negative control mechanisms 1, and loss-of-function mutations can paradoxically enhance T-cell effector functions in tumor-infiltrating lymphocytes 4. Clinically, SH2D2A polymorphisms contribute to autoimmune disease susceptibility. Short GA repeat alleles (GA₁₃-GA₁₆) in the promoter are associated with multiple sclerosis, with affected individuals showing reduced TSAd expression after CD4+ T-cell activation 56. Similar associations exist for juvenile rheumatoid arthritis, particularly in HLA-DRB1*08-positive patients 1. These findings suggest SH2D2A variants represent important biomarkers for autoimmune disease susceptibility 7, while somatic SH2D2A mutations in tumor-infiltrating lymphocytes may enhance antitumor immunity and response to checkpoint inhibitors 4.